ERBB2 and breast cancer: For instance, in HER2‐positive breast cancer patients, where antibody‐dependent cell‐mediated cytotoxicity (ADCC) and phagocytosis (ADCP) are the major mechanisms of action of anti‐HER2 treatment,21, 22 sTILs infiltration was regarded as a strong predictive and prognostic factor in both early16, 17, 19, 23, 24 and late setting.25